Fundamentals of population pharmacokinetic modelling: validation methods

CMT Sherwin, TKL Kiang, MG Spigarelli… - Clinical …, 2012 - Springer
Population pharmacokinetic modelling is widely used within the field of clinical
pharmacology as it helps to define the sources and correlates of pharmacokinetic variability …

[图书][B] The art of modeling

PL Bonate - 2006 - Springer
The focus of this book is primarily on the development of pharmacokinetic and
pharmacokinetic-pharmacodynamic models. Models that are reported in the literature are …

Parametric approaches in population pharmacokinetics

M Guidi, C Csajka, T Buclin - The Journal of Clinical …, 2022 - Wiley Online Library
Population pharmacokinetic (popPK) approaches have spread widely throughout clinical
pharmacology research, and every clinician should have some understanding of them. After …

Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance

W Byon, MK Smith, P Chan, MA Tortorici… - CPT …, 2013 - Wiley Online Library
This tutorial describes the development of a population pharmacokinetic (Pop PK) analysis
guidance within Pfizer, which strives for improved consistency and efficiency, and a more …

Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose …

M Ulldemolins, D Soy, M Llaurado-Serra… - Antimicrobial agents …, 2015 - Am Soc Microbiol
Meropenem dosing in critically ill patients with septic shock and continuous renal
replacement therapy (CRRT) is complex, with the recommended maintenance doses being …

Population pharmacokinetics of benznidazole in adult patients with Chagas disease

D Soy, E Aldasoro, L Guerrero, E Posada… - Antimicrobial agents …, 2015 - Am Soc Microbiol
The aim of the present study was to build a population pharmacokinetic (popPK) model to
characterize benznidazole (BNZ) pharmacokinetics in adults with chronic Chagas disease …

Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study

Z Xu, E Bouman‐Thio, C Comisar… - British journal of …, 2011 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Interleukin (IL)‐6 is a cytokine known
for pleiotropic and pro‐inflammatory functions. IL‐6 is involved in various disease processes …

Mechanism‐based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers

A Yassen, E Olofsen, R Romberg… - Clinical …, 2007 - Wiley Online Library
The objective of this study was to characterize the pharmacokinetic/pharmacodynamic
(PK/PD) relationship of buprenorphine and fentanyl for the respiratory depressant effect in …

Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics

A Yassen, E Olofsen, A Dahan, M Danhof - Journal of Pharmacology and …, 2005 - ASPET
The objective of this investigation was to characterize the pharmacokinetic/
pharmacodynamic correlation of buprenorphine and fentanyl for the antinociceptive effect in …

A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation

J Ding, Y Wang, W Lin, C Wang, L Zhao, X Li… - Clinical …, 2015 - Springer
Abstract Background and Objective Valproic acid (VPA) follows a non-linear
pharmacokinetic profile in terms of protein-binding saturation. The total daily dose regarding …